BLAINJECTIONINJECTABLE
Approved
Aug 2021
Lifecycle
Peak
Competitive Pressure
30/100
Clinical Trials
1
Data completeness
2/8 — Basic
Drug data last refreshed 5h ago · AI intelligence enriched 1mo ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
SKYTROFA is a recombinant human growth hormone (somatropin) approved by the FDA in August 2021 for pediatric growth hormone deficiency. It is a long-acting pegylated formulation designed to reduce injection frequency compared to daily growth hormone therapies. The drug works by replacing or supplementing endogenous growth hormone to promote linear growth in children with GHD.
Peak
Product is in peak commercial phase with moderate competitive pressure (30), suggesting active market growth and expansion of sales and marketing teams.
Mechanism of Action
Pharmacologic Class:
Recombinant Human Growth Hormone
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (1)
A US Non-interventional, Effectiveness and Safety Study of Patients Treated With SKYTROFA
Started Mar 2023
900 enrolled
Growth Hormone Deficiency
Career Relevance
SKYTROFA offers career opportunities in a pediatric endocrinology niche with a differentiated mechanism (once-weekly dosing). Working on this product in peak lifecycle provides exposure to specialty pharmaceutical commercial execution, payer strategy, and managed care for rare pediatric conditions.
Brand Manager
Worked on SKYTROFA at Ascend Therapeutics? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.